Ibio Inc (IBIO)
$1.81 0.00 (0.00%)
5:21 EST IBIO Stock Quote Delayed 30 Minutes
Previous Close -
Market Cap 28.85M
PE Ratio -1.06
Volume (Avg. Vol.) 387
Day's Range 1.81 - 1.81
52-Week Range 0.76 - 7.45
Dividend & Yield N/A (N/A)
IBIO Stock Predictions, Articles, and Ibio Inc News
- From InvestorPlace
- From the Web
These penny stocks are companies that have a crucial year ahead in terms of industry turnaround or company specific product development.
With iBio making key executive-level appointments and recording excellent fiscal stats, IBIO stock's value proposition is hard to ignore.
In the midst of an expensive market, traders are turning to penny stocks as a cheaper alternative. But avoid these seven risky penny names.
Ibio (IBIO) stock is on the rise Thursday despite a lack of news coming out today that would result in the movement today.
We may be seeing some sector rotation, and many companies that have made big moves in recent weeks have stocks under $10.
Shares of IBIO stock are taking off on Friday after an analyst from Cantor Fitzgerald initiated an Overweight rating and $3 price target.
Technology and biotech stocks brought in more winning picks than usual, thanks partly to the strong stock market. Here are some of my best calls.
It’s the time to clean house and make portfolio space for stronger investment opportunities during 2021. Here are 7 stocks to sell.
Investors bought the Covid-19 hype in IBIO stock. With little progress made, however, reality is setting in, which means the fade should continue.
The IBIO stock price is down, but that doesn't mean the company's in trouble. In fact, the data shows that iBio's fiscal health is improving.
While its shot at pioneering a novel coronavirus vaccine has passed, iBio and its IBIO stock could benefit from other medical breakthroughs.
Biotech innovator IBIO stock has been tossed around based on iBio’s COVID-19 vaccine progress, but its FastPharma tech is the long-term play.
Ibio (IBIO) is seeing shares of IBIO stock soar higher on Wednesday following news of a contract for the biotech company.
iBio has a long-standing relationship with the United States defense industry. But that hasn't enough to give IBIO stock a leg up in the Covid-19 race.
One of the more intriguing high-risk, high-reward ideas in the Covid-19 space, IBIO stock had an opportunity to distinguish itself. But with the vaccine race heating up, the dangers outweigh the possibilities.
iBio’s first-quarter included steep losses and not much else. If IBIO stock is to rise to $2, investors need some good news to chew on.
The latest in IBIO news: stay away from IBIO stock, which has over-issued shares to survive. The stock remains below the average issue price.
From Market News Video
From The Motley Fool
Navellier RatingsPowered by Portfolio Grader